Bioactive natural products in COVID-19 therapy

Zhonglei Wang; Ning Wang; Liyan Yang; Xian-Qing Song

doi:10.3389/fphar.2022.926507

Bioactive natural products in COVID-19 therapy

Front Pharmacol. 2022 Aug 19:13:926507. doi: 10.3389/fphar.2022.926507. eCollection 2022.

Authors

Zhonglei Wang^{1

2}, Ning Wang³, Liyan Yang⁴, Xian-Qing Song³

Affiliations

¹ Key Laboratory of Green Natural Products and Pharmaceutical Intermediates in Colleges and Universities of Shandong Province, School of Chemistry and Chemical Engineering, Qufu Normal University, Qufu, China.
² School of Pharmaceutical Sciences, Tsinghua University, Beijing, China.
³ General Surgery Department, Ningbo Fourth Hospital, Xiangshan, China.
⁴ School of Physics and Physical Engineering, Qufu Normal University, Qufu, China.

Abstract

The devastating COVID-19 pandemic has caused more than six million deaths worldwide during the last 2 years. Effective therapeutic agents are greatly needed, yet promising magic bullets still do not exist. Numerous natural products (cordycepin, gallinamide A, plitidepsin, telocinobufagin, and tylophorine) have been widely studied and play a potential function in treating COVID-19. In this paper, we reviewed published studies (from May 2021 to April 2022) relating closely to bioactive natural products (isolated from medicinal plants, animals products, and marine organisms) in COVID-19 therapy in vitro to provide some essential guidance for anti-SARS-CoV-2 drug research and development.

Keywords: COVID-19; SARS-CoV-2; cordycepin; gallinamide A; natural products; plitidepsin; telocinobufagin; tylophorine.

Publication types

Review